Event Data
{"article_title":"Radiotherapy of lymphomas.","author":"Balosso J, Missohou F, Antoni D, Hennequin C, Mah\u00e9 MA, Simon L, Demoor-Goldschmidt C","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"388","page_count":"","accession_number":"34953716","doi":"10.1016\/j.canrad.2021.11.007","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Hodgkin Disease radiotherapy; Lymphoma, Non-Hodgkin radiotherapy; France; Hodgkin Disease pathology; Humans; Lymphoma, Non-Hodgkin pathology; Organs at Risk; Patient Positioning; Quality of Life; Radiation Oncology; Radiotherapy Dosage; Radiotherapy, Conformal methods; Radiotherapy, Intensity-Modulated methods; Tumor Burden","interest_area":["Oncology"," Radiology"],"abstract":"Radiotherapy for Hodgkin lymphomas has evolved a lot over time, but still plays an important role, almost always in addition to chemotherapy, for the management of the early stages. The major objective is to preserve the quality of life of patients who will be cured from this disease in the vast majority of cases. Also, the personalization of the indications for the purpose of de-escalating toxicity is very refined and is essentially based on the pre- and pertherapeutic assessment by FDG-PET. The indications for radiotherapy are more limited for non-Hodgkin lymphomas, but the same principles are found, regardless of the histological type. We present the update of the recommendations of the French society of oncological radiotherapy for radiotherapy of lymphomas, which remains a very evolving field in terms of therapeutic strategy and evaluation. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953716","isPdfLink":false,"isSAML":true,"an":"34953716","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 388-396. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"Radiotherapy for Hodgkin lymphomas has evolved a lot over time, but still plays an important role, almost always in addition to chemotherapy, for the management of the early stages. The major objective is to preserve the quality of life of patients who will be cured from this disease in the vast majority of cases. Also, the personalization of the indications for the purpose of de-escalating toxicity is very refined and is essentially based on the pre- and pertherapeutic assessment by FDG-PET. The indications for radiotherapy are more limited for non-Hodgkin lymphomas, but the same principles are found, regardless of the histological type. We present the update of the recommendations of the French society of oncological radiotherapy for radiotherapy of lymphomas, which remains a very evolving field in terms of therapeutic strategy and evaluation.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/dx.doi.org\/doi:10.1017\/S0022215106000831","no_of_pages":"","authored_by":"Balosso J, Missohou F, Antoni D, Hennequin C, Mah\u00e9 MA, Simon L, Demoor-Goldschmidt C","additionalInfo":{"Authored_By":"D W Aird, P Puttasiddaiah, S Berry, C Spyridakou, M Kumar","Published_Date":"2006-05-01","Source":"Journal of Laryngology & Otology; May2006, Vol. 120 Issue 5, p371-374, 4p","Languages":"English","Subjects":"TUMORS, PATHOLOGY, CYSTS (Pathology), ONCOLOGY","Title_Abbreviations":"Journal of Laryngology & Otology","Volume":"120"},"header":{"DbId":"edb","DbLabel":"Complementary Index","An":"34953716","RelevancyScore":"833","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"832.625671386719"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=edb&AN=34953716&authtype=shib&custid=ns346513&group=main&profile=eds"}
Additional Info
["D W Aird, P Puttasiddaiah, S Berry, C Spyridakou, M Kumar","2006-05-01","Journal of Laryngology & Otology; May2006, Vol. 120 Issue 5, p371-374, 4p","English","TUMORS, PATHOLOGY, CYSTS (Pathology), ONCOLOGY","Journal of Laryngology & Otology","120"]
Description
Objective: The aim of this study was to identify the distribution of parotid tumours within the gland in relation to the facial nerve branches. Documentation revealing such a relationship has not been reported previously.Method: A prospective study involving 111 patients was carried out over a period of 18 years in a specialist otolaryngology unit within a district general hospital. The relationship of the facial nerve to the tumour was graded into six types. The grading system was then employed to categorize each case.Results: More than two-thirds of the tumours were pleomorphic adenomas. The majority of these were located in the body and not in the tail of the parotid gland. In 50 per cent of these cases, the tumour was in close association with the two major divisions of the facial nerve. In the case of Warthin's tumours, 47 per cent were located in the tail, below the lower division of the facial nerve. [ABSTRACT FROM AUTHOR]
